Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin

Journal of Medicinal Chemistry

Volumn 49, Issue 19, 2006, Pages 5664-5670

  Kim, Do Yoon ^a   Kim, Kyun Hwan ^b   Kim, Nam Doo ^d   Lee, Ki Young ^c   Han, Cheol Kyu ^d   Yoon, Jeong Hyeok ^d   Moon, Seung Kee ^e   Lee, Sung Sook ^e   Seong, Baik L ^a,f  

^a Yonsei University   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Equispharm Co Ltd   (South Korea)

^e Chong Kun Dang Research Institute   (South Korea)

^f Protheon Incorporated   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,5 DIMETHOXYPHENYL) 3 [4 (DIMETHYLAMINO)PHENYL] 2 METHYL 2 PROPEN 1 ONE; ANTIMITOTIC AGENT; CHALCONE DERIVATIVE; COLCHICINE; PODOPHYLLOTOXIN; PROTEIN INHIBITOR; TUBULIN;

ARTICLE; BIOLOGICAL ACTIVITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; EPITHELIUM CELL; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; KIDNEY EPITHELIUM; MICROTUBULE ASSEMBLY; MOLECULAR MODEL; PHARMACOPHORE;

CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONE; COLCHICINE; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL CELLS; HUMANS; MODELS, MOLECULAR; PODOPHYLLOTOXIN; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 33748876011     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050761i     Document Type: Article

References (24)

1. Downing, K. H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu. Rev. Cell Dev. Biol. 2000, 16, 89-111.
2. Walczak, C. E. Microtubule dynamics and tubulin interacting proteins. Curr. Opin. Cell Biol. 2000, 12, 52-56.
3. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277, 665-667.
4. Weisenberg, R. C.; Borisy, G. G.; Taylor, E. W. The colchicine-binding protein of mammalian brain and its relation to microtubules. Biochemistry 1968, 7, 4466-4479.
5. Edwards, M. L.; Stemerick, D. M.; Sunkara, P. S. Chalcones: a new class of antimitotic agents. J. Med. Chem. 1990, 33, 1948-1954.
6. Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev. 1998, 18, 259-296.
7. Nogales, E.; Wolf, S. G.; Downing, K. H. Structure of the alpha beta tubulin dimer by election crystallography. Nature 1998, 391, 199-203.
8. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995, 55, 2325-2333.
9. Long, B. H.; Carboni, J. M.; Wasserman, A. J.; Cornell, L. A.; Casazza, A. M.; Jensen, P. R.; Lindel, T.; Fenical, W.; Fairchild, C. R. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res. 1998, 58, 1111-1115.
10. Rai, S. S.; Wolff, J. Localization of the vinblastine-binding site on beta-tubulin. J. Biol. Chem. 1996, 271, 14707-14711.
11. Peyrot, V.; Leynadier, D.; Sarrazin, M.; Briand, C.; Menendez, M.; Laynez, J.; Andreu, J. M. Mechanism of binding of the new antimitotic drug MDL 27048 to the colchicine site of tubulin: equilibrium studies. Biochemistry 1992, 31, 11125-11132.
12. Goodsell, D. S.; Olson, A. J. Automated docking of substrates to proteins by simulated annealing. Proteins 1990, 8, 195-202.
13. Morris, G. M.; Goodsell, D. S.; Huey, R.; Olson, A. J. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comput.-Aided Mol. Des. 1996, 10, 293-304.
14. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
15. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
16. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
17. Shin, E. C.; Shin, J. S.; Park, J. H.; Kim, J. J.; Kim, H.; Kim, S. J. Expression of Fas-related genes in human hepatocellular carcinomas. Cancer Lett. 1998, 134, 155-162.
18. Park, J. G.; Lee, J. H.; Kang, M. S.; Park, K. J.; Jeon, Y. M.; Lee, H. J.; Kwon, H. S.; Park, H. S.; Yeo, K. S.; Lee, K. U. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 1995, 62, 276-282.
19. AutoDock, version 3.0.5; http://www.scripps.edu/mb/olson/doc/autodock/.
20. Ravelli, R. B.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004, 428, 198-202.
21. Gaussian 98 User Guide; Gaussian, Inc.: Pittsburgh, PA, 1998.
22. Lawrence, N. J.; McGown, A. T. The chemistry and biology of antimitotic chalcones and related enone systems. Curr. Pharm. Des. 2005, 11, 1679-1693.
23. Robinson, T. P.; Ehlers, T.; Hubbard, R. B., IV; Bai, X.; Arbiser, J. L.; Goldsmith, D. J.; Bowen, J. P. Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. Bioorg. Med. Chem. Lett. 2003, 13, 115-117.
24. Chun, E.; Lee, K. Y. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 2004, 12, 771-779.